Cannabinoids for Epilepsy - Real Data, at Last.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Research and Clinical Practice Involving the Use ofPharmaceuticals (Basel, Switzerland) · 2024
   Review
2. Medical cannabis regulation: an overview of models around the world with emphasis on the Brazilian scenario.Journal of cannabis research · 2022
   Review
3. From an Alternative Medicine to a New Treatment for Refractory Epilepsies: Can Cannabidiol Follow the Same Path to Treat Neuropsychiatric Disorders?Frontiers in psychiatry · 2021
   Review
4. Attitudes of Irish patients with chronic pain towards medicinal cannabis.Irish journal of medical science · 2019
   Article
5. The case for medicinal cannabis.Irish journal of medical science · 2018
   Article
6. Clinical studies with Cannabis in India - A need for guidelines for the investigators and ethics committees.Perspectives in clinical research
   Article

Corrections and comments

• Comment on
  Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.2017

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as